Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma — Stella

Home/B-Cell Non-Hodgkin Lymphoma-Recurrent/CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

View on ClinicalTrials.gov

Recruiting

Back to B-Cell Non-Hodgkin Lymphoma-Recurrent trials

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Key details

Phase

Early testing

Sponsor

Nathan Denlinger

Collaborators

Bristol-Myers Squibb

Enrollment target

~18 participants

Started

January 2024

Primary completion

December 2026

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.